medical_devices
The latest news about medical_devices: headlines, AI summaries and the full story from every source.
- Johnson & Johnson Raises Full-Year Sales Outlook Despite Medical Device Concerns
- AngioDynamics Shares Drop Despite Better-Than-Expected Q1 Earnings
- Edwards Lifesciences Receives FDA Approval for Expandable Pediatric Pulmonary Valve
- Grail's Stock Surges After FDA Advisory Committee Endorses Multi-Cancer Early Detection Test
- Boston Scientific Secures $135.7M Contract for Cardiovascular Products
- Grail Stock Surges Over 50% After FDA Committee Votes in Favor of Galleri MCED Test
- TriSalus Receives FDA Clearance for TriNav Advance Device, Stock Rises
- Medtronic Raises Fiscal Outlook Amid Strong Heart Device Demand
- Baron SMID Cap ETF Exits Insulet Corporation Amid Competitive Pressures
- Intuitive Surgical Maintains Procedure Growth Outlook Amid U.S. Slowdown and China Challenges
- Jaguar LAA Acquires Assets of the Laminar Program from Johnson & Johnson
- Medtronic Raises Fiscal Outlook on Strong Cardiovascular Performance
- Shoulder Innovations Launches N-22 Humeral Head After FDA Clearance
- Boston Scientific Announces Missed Financial Guidance Due to Cyberattack
- Stryker Stock Drops After CFO Remarks
- Medtronic Reports Strong Q1 Earnings with Broad-Based Growth and Raised Guidance
- Boston Scientific Unlikely to Meet 2026 Sales, Profit Forecasts After Cyberattack
- Premarket Stock Movements: Peloton, Roivant Sciences, Boston Scientific Among Major Movers
- Electromed Reports Continued Growth Amid Leadership Transition
- Globus Medical Receives CE Mark for Excelsius3D Mobile X-ray System
- Medtronic Reports Strong Q1 Earnings, Raises Full-Year Guidance
- Dexcom and Abbott Await Medicare Coverage Expansion for Continuous Glucose Monitors
- Baxter International Reports Strong Q2 Earnings with Sales Growth and Guidance Hike
- Stryker Reports Strong Q2 Earnings Amid Recovery from Cybersecurity Incident
- Stryker Reports $6.6 Billion Revenue for Q2 Amid Recovery from Cyberattack
- Baxter International Stock Performance and Analyst Ratings
- Baxter International Shares Rise 19% on Strong Q2 Earnings and Raised Guidance
- Beta Bionics Reports Strong Q2 Earnings with Sales Growth and Margin Expansion
- Boston Scientific Cuts Full-Year Profit Outlook Amid Slower Watchman Demand
- Integra LifeSciences Reports Strong Q2 Earnings, Reaffirms Full-Year Guidance
- Boston Scientific Lowers 2026 Guidance Due to Struggles in Key Businesses
- Beta Bionics Outlines Mint Launch by End of Q2 2027 and Raises Gross Margin Outlook for 2026
- Boston Scientific Reports Strong Q2 Results and Raises Full-Year Outlook
- GE HealthCare Exceeds Quarterly Profit Estimates Amid Strong Imaging Demand and Tariff Refunds
- Boston Scientific Lowers Annual Profit Forecast Due to Slower Watchman Device Adoption
- Abbott Raises Profit Forecast Amid Strong Performance from Diagnostics and Medical Devices
- Edwards Lifesciences Reports Strong Q2 Results with Raised Full-Year Guidance
- AtriCure Reports Strong Q2 Earnings with Revenue Growth and Return to Profitability
- AtriCure Updates Revenue Guidance to $602M-$610M for 2026 and Raises Adjusted EBITDA Outlook
- Johnson & Johnson receives FDA authorization for Ottava surgical robot
- Johnson & Johnson Receives FDA Authorization for Ottava Surgical Robot
- Intuitive Surgical Reports Strong Q2 Earnings Despite Stock Sell-off
- Intuitive Surgical shares fall amid concerns over insurance plan changes impacting medtech demand
- Abbott Raises 2026 Profit Forecast Due to Strong Performance in Diagnostics and Heart Devices
- Abbott Laboratories Reports Strong Q2 Earnings and Raises Full-Year Outlook
- Nuwellis Secures U.S. Patent for Dual-Lumen Catheter Technology
- Kestra Medical Technologies Reports Strong Q4 Revenue Growth and Provides Fiscal 2027 Guidance
- Johnson & Johnson Reports Strong Q2 Earnings and Sales Growth
- Kestra Medical Technologies (NASDAQ: KMTS) Forecasts $137M Revenue for FY2027 with High Gross Margin Target
- AngioDynamics Provides FY2027 Guidance with $336M-$341M Net Sales and Adjusted EBITDA of $13M-$16M